These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 26228372)

  • 1. Ribavirin-free treatment may soon be a reality.
    Al-Judaibi B
    Saudi J Gastroenterol; 2015; 21(4):260-1. PubMed ID: 26228372
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatitis C position statement: Taking a stand and standing by it.
    Sanai FM; Alghamdi AS; Alghamdi MY
    Saudi J Gastroenterol; 2015; 21(4):262-3. PubMed ID: 26228373
    [No Abstract]   [Full Text] [Related]  

  • 3. SASLT position statement on the direct-acting antiviral agents for the treatment of hepatitis C virus infection.
    Alghamdi AS; Alqutub A; Abaalkhail F; Sanai FM; Alghamdi H; Altraif I; Alswat KA; Alghamdi MY; Babatin MA; Alfaleh FZ
    Saudi J Gastroenterol; 2015; 21(2):60-3. PubMed ID: 25843190
    [No Abstract]   [Full Text] [Related]  

  • 4. Ribavirin: is it a mutagen for hepatitis C virus?
    Perelson AS; Layden TJ
    Gastroenterology; 2007 May; 132(5):2050-2. PubMed ID: 17484896
    [No Abstract]   [Full Text] [Related]  

  • 5. Interferon/pegylated interferon and ribavirin in HCV-associated kidney disease with or without cryoglobulinemia.
    Bruchfeld A; Lindahl K; Stahle L; Schvarcz R
    J Hepatol; 2006 Feb; 44(2):432-3; author reply 433. PubMed ID: 16338023
    [No Abstract]   [Full Text] [Related]  

  • 6. Analysis of sequence configurations of the PKR-interacting HCV proteins from plasma and PBMC as predictors of response to interferon-alpha and ribavirin therapy in HIV-coinfected patients.
    Bolcic F; Bull L; Martinez L; Reynoso R; Salomon H; Arduino R; Barnett B; Quarleri J
    Intervirology; 2008; 51(4):261-4. PubMed ID: 18824873
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of hepatitis C. Different modalities based on viral genotype].
    Pariente A
    Rev Prat; 2003 Jun; 53(11):1175-6. PubMed ID: 15185639
    [No Abstract]   [Full Text] [Related]  

  • 8. HCV findings presented at EASL: long-term follow-up and the criteria of a cure.
    Lang L
    Gastroenterology; 2007 Jun; 132(7):2282-3. PubMed ID: 17570197
    [No Abstract]   [Full Text] [Related]  

  • 9. Hepatitis B and C virus resistance to antiviral therapies--EASL-AASLD-APASL-ALEH-IASL conference.
    Buti M
    IDrugs; 2008 Apr; 11(4):239-41. PubMed ID: 18379952
    [No Abstract]   [Full Text] [Related]  

  • 10. Letter: self-pay behaviour patients with chronic hepatitis C who required direct acting anti-viral urgently in a real-world setting.
    Chen TM; Li YC; Huang PT
    Aliment Pharmacol Ther; 2016 Mar; 43(6):752. PubMed ID: 26876292
    [No Abstract]   [Full Text] [Related]  

  • 11. Mutant Ninja viruses.
    Foster GR
    Hepatology; 2015 Feb; 61(2):421-3. PubMed ID: 25266372
    [No Abstract]   [Full Text] [Related]  

  • 12. Recombinant hepatitis C viruses that might hamper accurate genotype classification and choice of treatment with direct-acting agents, southeastern France.
    Colson P; Borentain P; Dhiver C; Benhaim S; Gerolami R; Tamalet C
    Hepatology; 2016 Apr; 63(4):1400-2. PubMed ID: 26418048
    [No Abstract]   [Full Text] [Related]  

  • 13. Letter: safety and efficacy of sofosbuvir plus daclatasvir with ribavirin for 12 weeks in Chinese treatment-experienced cirrhotic genotype 1b patients with HCV.
    Zeng QL; Li CX; Zhang DW; Li W; Xu GH; Yu ZJ
    Aliment Pharmacol Ther; 2016 Apr; 43(7):842-3. PubMed ID: 26932414
    [No Abstract]   [Full Text] [Related]  

  • 14. The end of the beginning for hepatitis C treatment.
    Dieterich D
    Hepatology; 2012 Mar; 55(3):664-5. PubMed ID: 22174100
    [No Abstract]   [Full Text] [Related]  

  • 15. The importance of rapid viral suppression in the era of directly acting antiviral therapy for hepatitis C virus.
    Jenkins ET; Jensen DM
    Infect Dis Clin North Am; 2012 Dec; 26(4):879-91. PubMed ID: 23083821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C virus infection in Taiwan: Past, present, and future.
    Kao JH
    J Formos Med Assoc; 2016 Feb; 115(2):65-6. PubMed ID: 26228687
    [No Abstract]   [Full Text] [Related]  

  • 17. [Hepatitis C virus genotype 4: epidemiology and treatment].
    Castera L; Morice Y; Grando V; Bon C; Dény P; Roulot D
    Gastroenterol Clin Biol; 2003 Jun; 27(6-7):596-604. PubMed ID: 12910223
    [No Abstract]   [Full Text] [Related]  

  • 18. Quantum leaps, microeconomics, and the treatment of patients with hepatitis C and HIV coinfection.
    Saag MS
    JAMA; 2014 Jul 23-30; 312(4):347-8. PubMed ID: 25038351
    [No Abstract]   [Full Text] [Related]  

  • 19. Focus.
    Samuel D
    J Hepatol; 2010 Jan; 52(1):3-4. PubMed ID: 19923033
    [No Abstract]   [Full Text] [Related]  

  • 20. Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposure.
    Yu ML; Dai CY; Huang JF; Chuang WL
    Hepatology; 2008 Sep; 48(3):1019-20; author reply 1020-1. PubMed ID: 18756469
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.